Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISA101b and Cemiplimab in Recurrent/Metastatic HPV16+ Oropharyngeal Cancer
NCT04398524Phase 2Active, not recruiting
- Sponsor
- ISA Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Jun 2024
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 9
01
Overview
A Phase 2 trial of SLP-HPV-01 in oropharyngeal cancer, sponsored by ISA Pharmaceuticals. Started Jul 2021; status: active, not recruiting.
02
Drugs
SLP-HPV-01
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT04398524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398524.